Aclaris Therapeutics, Inc. (NASDAQ:ACRS) will be issuing its earnings data before the market opens on Wednesday, November 1st. Analysts expect the company to announce earnings of ($0.86) per share for the quarter.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.12. On average, analysts expect Aclaris Therapeutics to post $-3.1 EPS for the current fiscal year and $-3.43 EPS for the next fiscal year.

Shares of Aclaris Therapeutics, Inc. (ACRS) opened at 25.57 on Wednesday. Aclaris Therapeutics, Inc. has a 12 month low of $20.15 and a 12 month high of $33.25. The firm’s market cap is $683.64 million. The firm has a 50 day moving average price of $26.36 and a 200-day moving average price of $26.79.

A number of research firms have issued reports on ACRS. BidaskClub upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Zacks Investment Research upgraded Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price objective for the company in a report on Tuesday, October 10th. Cantor Fitzgerald set a $50.00 price objective on Aclaris Therapeutics and gave the company a “buy” rating in a report on Wednesday, October 4th. ValuEngine cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, September 12th. Finally, JMP Securities restated an “outperform” rating and issued a $39.00 price objective on shares of Aclaris Therapeutics in a report on Friday, September 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. Aclaris Therapeutics presently has a consensus rating of “Buy” and an average price target of $39.20.

In related news, Director Andrew N. Schiff acquired 108,601 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The stock was bought at an average price of $23.02 per share, for a total transaction of $2,499,995.02. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 16.30% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Earnings History for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with's FREE daily email newsletter.